ID   HCC40-CL
AC   CVCL_VG04
DR   Wikidata; Q54881714
RX   PubMed=27279800;
CC   Population: Chinese.
CC   Doubling time: ~43 hours (PubMed=27279800).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln104Pro (c.311A>C); Zygosity=Unspecified (PubMed=27279800).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
ST   Source(s): PubMed=27279800
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11,12
ST   D13S317: 8,9
ST   D16S539: 12
ST   D18S51: 17,18
ST   D19S433: 13,15
ST   D21S11: 28,32.2
ST   D2S1338: 18,21
ST   D3S1358: 15,16
ST   D5S818: 11,13
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 22,25
ST   TH01: 6,9
ST   TPOX: 8,9
ST   vWA: 14,19
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 19-12-24; Version: 8
//
RX   PubMed=27279800; DOI=10.1186/s12935-016-0322-5; PMCID=PMC4898407;
RA   Cheung P.F.-Y., Yip C.-W., Ng L.W.-C., Lo K.-W., Chow C., Chan K.-F.,
RA   Cheung T.-T., Cheung S.-T.;
RT   "Comprehensive characterization of the patient-derived xenograft and
RT   the paralleled primary hepatocellular carcinoma cell line.";
RL   Cancer Cell Int. 16:41.1-41.11(2016).
//